Q1 reporting continues

This week, Castellum and Balder reported Q1 results, Wihlborgs announced a new lease, and SBB corrected 2023 profits and dissolved Unobo. Norges Bank has signalled interest rates might stay higher for longer. K2A has halted preference dividend payments. The weighted-average implied EBITDA yields on the stocks we cover are 4.69% for 2024e and 4.97% for 2025e.

+450bp gross margin underpins turnaround

A strong start to 2024 with 5-13% divisional profit beats. +450bp gross margin expansion validates turnaround story. BUY on deep values and turnaround, TP DKK 235 (225).

GN Group (Buy, TP: DKK250.00) - Gaining confidence in management

The Q1 results beat our expectations and consensus, with c5% organic growth and a 12.5% EBITA margin, driven by the Hearing division, while Enterprise and Gaming & Consumer saw c0% organic revenue growth in still-muted markets. The 2024 guidance was maintained for organic sales growth of 2–8%, an EBITA margin of 12–14%, and FCF of >DKK700m. At the upcoming CMD, we expect focus to be on One-GN and market outlook. We reiterate our BUY, and have raised our target price to DKK250 (230).

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 02/05/2024

...

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 05/02/2024

We are removing GALP from our ODDO BHF European Large Caps list. The stock has chalked up a performance of +31.3% since its inclusion in the list on 20 March. Our analyst is adopting today a Neutral recommendation (vs Outperform) on the stock. - ...

GN Store Nord : Strong hearing aid business, stabilisation at Enterpri...

>Q1 review – Strong beat on bottom line - GN Store Nord achieved Q1 revenues of DKK 4,303m (+2.1% y-o-y, 0%/+1% vs ODDO BHF/consensus). Q1 adj. EBITA reached DKK 538m (+218% y-o-y, margin 12.5%), which was a strong beat by 35% of our estimates and by 32% vs consensus. EPS reached DKK 1.74 (vs DKK 0.87/0.85 expected). The 2024 guidance is confirmed.GN Hearing - Excellent organic growth on new Nexia platform - GN Hearing’s Q1 revenues of DKK 1,737m (+7....

Growth and margin beat in key business'

Upgrade or not to upgrade, that is the question

Telia Company AB: 1 director

A director at Telia Company AB bought 14,100 shares at 2.140EUR and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

Weekly Real Estate Matrix

Performance and valuation data for Nordic real estate stocks as of 26 April 2024.

Q1 reporting season kicks off

Q1 reporting season kicked off this week, with results from Nyfosa, Entra, Wallenstam, Fabege, KMC Properties, Pandox, and Catena. In other news, Public Property Invest is to be listed on the Oslo stock exchange on 29 April. The weighted-average implied EBITDA yields on the stocks we cover are 4.75% for 2024e and 5.04% for 2025e.

Telia Company (Buy, TP: SEK33.00) - Soft Q1, but limited revisions

Telia reported Q1 service revenue, EBITDA, and cash flow below consensus. However, with the SEK300m/year service agreement after the sale of the Danish operation, we have made limited revisions to our 2024–2025e service revenue, EBITDA, and cash flow. We reiterate our BUY but have cut our target price to SEK33 (35).

Swedish Orphan Biovitrum (Buy, TP: SEK335.00) - Strong start to 2024

The Q1 earnings were above our forecast, even though some of the positive effects were one-offs (manufacturing revenues, among others). We believe Vonjo sales have bottomed out and we should be back at QOQ growth from Q2. The haemophilia franchise enjoyed stronger than expected growth, but some of this was due to phasing between quarters (hence this might hurt Q2 sales slightly). We reiterate our BUY and have increased our target price to SEK335 (320).

Q1 shows core SOBI sales model works

Strong Q1 numbers, 20% CER growth and 5-15% adj EBITA beat. Vonjo questions remain, but Q1 shows that SOBI sales model works. EPS +1-2% and unchanged BUY, as core case is reaffirmed.

Cash flow volatility was not appreciated

Q1: solid underlying growth and reiterated FCF outlook, but the market focused on the (weak) volatile cash flow in Q1. Uncertainty, limited re-rating potential and soft valuation support. HOLD.

Telia (Buy, TP: SEK33, +24%) Q1 24: Weak headline numbers, but due to...

Telia has reported a weak set of headline numbers, but consensus had not fully adjusted for the one-off items the company had flagged before the quarter. Adjusting for these items, EBITDA is c-0.5% light only. Structural OCF (SOCF) is also light vs consensus, but again, this was flagged as a phasing issue pre the quarter, and again it looks like the messaging was not fully incorporated into numbers.

Q1'24: strong sales and decent margin

Slight miss but expect limited cons revisions

GN Group (Buy, TP: DKK230.00) - Time to rebuild credibility

We forecast Q1 organic sales growth of 3.0% YOY (consensus 2.8%) and an EBITA margin of 9.7% (consensus 9.6%). We see Hearing as starting well, and despite still-negative growth in Enterprise, we expect unchanged 2024 guidance. The upcoming CMD offers management scope to rebuild credibility, and we expect updated long-term targets to reflect “One-GN”. We reiterate our BUY and have raised our target price to DKK230 (215).